For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and Tafamidis meglumine represents a genuine change. These innovative therapies stabilize the transthyretin protein, slowing its damaging build-up and alleviating the burden of the condition . Individuals are now reporting i